| [1] Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC[J]. Lung Cancer, 2011, 71(1):3-10.[2] Choi KJ, Piao YJ, Lim MJ, et al. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia-and cisplatin-induced cell death[J]. Cancer Res, 2007, 67(8):3654-3662.[3] Han X, Yoon SH, Ding Y, et al. Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells[J]. Oncol Rep, 2010, 23(4):1053-1062.[4] Qian Z, Zhao X, Jiang M, et al. Downregulation of cyclophilin A by siRNA diminishes non-small cell lung cancer cell growth and metastasis via the regulation of matrix metallopeptidase 9[J]. BMC Cancer, 2012, 12:442.[5] Handschumacher RE, Harding MW, Rice J, et al. Cyclophilin:a specific cytosolic binding protein for cyclosporin A[J]. Science, 1984, 226(4674):544-547.[6] Galat A. Variations of sequences and amino acid compositions of proteins that sustain their biological functions:An analysis of the cyclophilin family of proteins[J]. Arch Biochem Biophys, 1999, 371(2):149-162.[7] Lee J, Kim SS. An overview of cyclophilins in human cancers[J]. J Int Med Res, 2010, 38(5):1561-1574.[8] Zheng J, Koblinski JE, Dutson LV, et al. Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer[J]. Cancer Res, 2008, 68(19):7769-7778.[9] Qi YJ, He QY, Ma YF, et al. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma[J]. J Cell Biochem, 2008, 104(5):1625-1635.[10] Li M, Zhai Q, Bharadwaj U, et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147[J]. Cancer, 2006, 106(10):2284-2294.[11] Hamilton G. Cyclophilin A as a target of cisplatin chemosensitizers [J]. Curr Cancer Drug Targets, 2014, 14(1):46-58.[12] Li Z, Zhao X, Bai S, et al. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma[J]. Mol Cell Proteomics, 2008, 7(10):1810-1823.[13] Howard BA, Zheng Z, Campa MJ, et al. Translating biomarkers into clinical practice:prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-samll cell lung cancer[J]. Lung Cancer, 2004, 46(3):3-10.[14] Campa MJ, Wang MZ, Howard B, et al. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer[J]. Cancer Res, 2003, 63(7):1652-1656.[15] Yang H, Chen J, Yang J, et al. Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal[J]. Biochem Biophys Res Commun, 2007, 361(3):763-767.[16] Al-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced non-small-cell lung cancer:meta-analysis of randomized controlled trials, with histology subgroup analysis [J]. Curr Oncol, 2012, 19(1):e9-e15.[17] 唐春兰, 杨和平, 周向东. DNA损伤修复与肺癌顺铂耐药机制的研究进展[J]. 中国肺癌杂志, 2011, 14(12):960-964.[18] Lee J. Novel combinational treatment of cisplatin with cyclophilin A inhibitors in human heptocellular carcinomas[J]. Arch Pharm Res, 2010, 33(9):1401-1409.[19] Vasko R, Mueller GA, von Jaschke AK, et al. Impact of cisplatin administration on protein expression levels in renal cell carcinoma:a proteomic analysis[J]. Eur J Pharmacol, 2011, 670(1):50-57.[20] Wei Y, Jinchuan Y, Yi L, et al. Antiapoptotic and proapoptotic signaling of cyclophilin A in endothelial cells[J]. Inflammation, 2013, 36(3):567-572.[21] Howard BA, Furumai R, Campa MJ, et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo[J]. Cancer Res, 2005, 65(19):8853-8860.[22] Zhang H, Chen J, Liu F, et al. CypA, a gene downstream of HIF-1alpha, promotes the development of PDAC[J]. PLoS One, 2014, 9(3):e92824.[23] Annunziata CM, Stavnes HT, Kleinberg L, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer[J]. Cancer, 2010, 116(13):3276-3284. |
